About On Target Laboratories
On Target Laboratories is a Healthcare company based in West Lafayette (United States) founded in 2010 by Phil S Low. Molecular imaging agents for cancer surgery are developed. On Target Laboratories has raised $116.5 million across 8 funding rounds from investors including Olympus, HHS and H.I.G. Capital. The company has 29 employees. Its chief executive, as recorded, is Chris Barys. On Target Laboratories offers products and services including CYTALUX. Its focus areas include Life Sciences, Oncology, Drugs and Ovarian Cancer. Its legal entity is ON TARGET LABORATORIES, INC. Its competitors include Lumicell Diagnostics, Averto Medical and US Medical Innovations; 3 of its 3 listed competitors have raised funding.
Company details
On Target Laboratories was founded in 2010 in West Lafayette, United States. Focus is placed on the biotechnology sector, where molecular imaging agents are developed to assist in cancer surgery. Fluorescent markers based on this technology are supplied to highlight cancerous tissue during procedures, allowing for targeted removal. Key roles are held by Phil S. Low as Founder and Chief Science Officer, and Chris Barys as CEO and President.
- Headquarters West Lafayette, United States
- Employees 29
- Founders Phil S Low
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ontargetlabs.com
- Social LinkedIn X
- Legal Name On Target Laboratories, Inc.
- Total Equity Funding$116.5M (USD)
in 8 rounds
- Latest Funding Round$30M (USD), Series C
Nov 2023
- InvestorsOlympus
& 12 more
- Employee Count29
Products & Services of On Target Laboratories
On Target Laboratories offers a comprehensive portfolio of products and services, including CYTALUX.
FDA-approved agent for detecting and illuminating tumors during cancer surgery.
Funding Insights of On Target Laboratories
On Target Laboratories has successfully raised a total of $116.5M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $116.5M
- Total Rounds 8
- Last Round Series C — $30M
- First Round $15M
(Mar 2014)
- Investors Count 13
All 8 funding rounds of On Target Laboratories with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $30M | Series C | – | Johnson & Johnson Innovation, Pension Fund | |
| Mar 2021 | $21M | Series B | – | Johnson & Johnson Innovation – JJDC, H.I.G. Capital | – |
| Mar 2018 | $11.1M | Series B | – | HIG BioHealth Partners, Elevate Ventures | – |
| Nov 2017 | $32.5M | Series B | – | Johnson & Johnson Innovation – JJDC | – |
| Apr 2016 | $5.2M | Series A | – | – | – |
| May 2015 | $1.7M | Series A | – | Purdue Foundry | – |
| Mar 2015 | $1.8M | Grant | – | – | |
| Mar 2014 | $15M | Series A | – | – |
13 investors in total: 12 institutional and 1 angel.
Investors in On Target Laboratories
On Target Laboratories has secured backing from 13 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Olympus, HHS and H.I.G. Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage healthcare investments are made by 3B Future Health Fund. | 3bfuturehealth.com | Luxembourg, Luxembourg | ||
Early-stage investments are made in diverse sectors by the firm. | elevateventures.com | Indianapolis, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Early-stage healthcare investments are made by this fund. | helsinninvestmentfund.com | Luxembourg, Luxembourg | ||
Support for technology commercialization and startup development is provided. | purduefoundry.com | West Lafayette, United States | ||
Private equity capital is invested in small and mid-sized businesses. | higcapital.com | Miami, United States | ||
| jnjinnovation.com | ||||
Retirement and savings solutions are provided by Pension Fund. | pensionfund.org | Indianapolis, United States | ||
Manufacturer of imaging and surgical products | 1919 | olympus-global.com | Tokyo, Japan | |
| higbio.com |
Investor details for On Target Laboratories
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of On Target Laboratories
19 people are tracked at On Target Laboratories (12 in leadership, 7 in team); the tracked headcount is 29.
| Name | Role | Group |
|---|---|---|
Phil S Low | Founder & Chief Science Officer | Leadership |
Chris Barys | CEO & President | Leadership |
Christopher Seekamp | Director of Process Development, CMC | Leadership |
Jessica Todd | Vice President Marketing | Leadership |
Anne Payen-Fornicola | Vice President of CMC | Leadership |
Ian Laswell | Vp, Commecial Operations | Leadership |
Philip Low | Co-Founder and Chief Science Officer | Leadership |
Pravin Gagare | Director, CMC | Leadership |
Juliet Bongianni, PhD | Director, Formulation Science and CMC | Leadership |
Tommy Lee | Vice President Clinical Operations | Leadership |
Shane Johnson | Executive Vice President Of Sales | Leadership |
Will Tillinghast | Vice President Of Sales | Leadership |
Andrew McCormick | Regional Sales Manager | Team |
Brian Michalski | Regional Sales Manager | Team |
Eugene Brohee | Regional Sales Manager | Team |
Andrew Burton | Regional Sales Manager | Team |
Sarah LaScola | Regional Sales Representative | Team |
Jake Walker | Account Manager | Team |
Patrick Precure | Account Manager | Team |
Complete people profiles for On Target Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of On Target Laboratories
3 dated milestones of On Target Laboratories across 13 years, from founding to its latest funding, stage changes and deals.
- Founded On Target Laboratories is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Series C, of $30.0M.
Competitors of On Target Laboratories
On Target Laboratories has 3 listed competitors in our database, 3 of them funded. They include Lumicell Diagnostics, Averto Medical and US Medical Innovations.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lumicell.com | 2008 | Wellesley, United States | $360.8M | 23 | Developer of fluorescence-guided imaging technologies to help surgeons detect residual cancer tissue during operations | |
| avertomed.com | 2016 | Fremont, United States | $33M | 18 | Medical devices for gastrointestinal disease patients are developed. | |
| usmedinnovations.com | 2010 | Takoma Park, United States | $11.18M | Electrosurgery and plasma technology for cancer treatment are developed. |
Detailed competitors of On Target Laboratories
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of On Target Laboratories
The website of On Target Laboratories (ontargetlabs.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 21.9% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as On Target Laboratories (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about On Target Laboratories
Complete news archive for On Target Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about On Target Laboratories
On Target Laboratories was founded in 2010 and raised its 1st funding round 4 years after it was founded.
On Target Laboratories is headquartered in West Lafayette, United States. It is registered at West Lafayette, Indiana, United States.
Chris Barys is the CEO of On Target Laboratories, as recorded in our data.
On Target Laboratories is a funded company, having raised a total of $116.5M across 8 funding rounds to date. The company's 1st funding round was a Series A of $15M, raised on Mar 2014.
On Target Laboratories has 29 employees.
On Target Laboratories was founded in 2010 in West Lafayette, United States. Focus is placed on the biotechnology sector, where molecular imaging agents are developed to assist in cancer surgery. Fluorescent markers based on this technology are supplied to highlight cancerous tissue during procedures, allowing for targeted removal. Key roles are held by Phil S. Low as Founder and Chief Science Officer, and Chris Barys as CEO and President.
On Target Laboratories's top competitors include Lumicell Diagnostics, Averto Medical and US Medical Innovations.
On Target Laboratories offers CYTALUX.
On Target Laboratories has 13 investors. Key investors include Olympus, HHS, H.I.G. Capital, Johnson & Johnson Innovation, and Pension Fund.
On Target Laboratories operates through On Target Laboratories, Inc..